Multinodular Primary Lung Cancer
Conditions
Interventions
Experimental group:Multimodal minimally invasive interventional treatment of multiple primary lung nodules assisted by artificial intelligence surgical planning software
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 80 years (at the time of signing the informed consent form), regardless of gender; 2.Clinically diagnosed with multiple primary lung cancer (MPLC) by multidisciplinary team (MDT) discussion, with 2 to 5 lesions, each with a maximum diameter = 3 cm; 3.Deemed unsuitable for surgery or intolerant to surgery based on initial clinical evaluation (e.g., poor cardiopulmonary function, underlying conditions such as diabetes, inability to undergo anesthesia, etc.); 4.Subjects who refuse surgery or choose to undergo minimally invasive treatment; 5.Patients with local recurrence after surgical resection or radiotherapy for primary lung cancer; 6.Eastern Cooperative Oncology Group (ECOG) performance status score of 0–1; 7.Expected survival = 6 months; 8.Able to understand the study objectives, voluntarily participate and sign the informed consent form, and willing to comply with the study requirements.
Exclusion criteria
Exclusion criteria: 1.Uncontrolled active infections: systemic fungal, bacterial, viral, or other infections, etc.; 2.Poor pulmonary function (severe emphysema, chronic obstructive pulmonary disease, severe pulmonary fibrosis, pneumothorax, etc.), etc.; 3.Severe bleeding tendency, platelet count 18 s, prothrombin activity < 40 %); 4.Anticoagulant and/or antiplatelet medications discontinued for less than 7 days before ablation; 5.Severe liver, kidney, heart, or brain dysfunction; 6.Participation in another clinical study of a device or drug within 1 month without reaching the primary endpoint; 7.Pregnant or breastfeeding women; 8.Patients with small cell lung cancer; 9.Other conditions deemed unsuitable for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease Control Rate;Local Progression-Free Survival; | — |
Countries
China
Contacts
Public ContactXu Zhu
Beijing Cancer Hospital
Outcome results
None listed